Cereno Scientific
Michael Holinstat is currently serving as a Professor of Pharmacology at the University of Michigan and also holds the position of Director of Translational Research at Cereno Scientific. He has had a successful career in academia and research, previously holding roles such as Vice President of Translational Research at VERALOX Therapeutics, Assistant Professor of Medicine at Thomas Jefferson University, and Postdoctoral Research Fellow at Vanderbilt University Medical Center. His educational background includes a PhD in Pharmacology from the University of Illinois College of Medicine, a Postdoctoral Research Fellow degree in Pharmacology from Vanderbilt University School of Medicine, and a Master of Science in Biology/Biological Sciences with a concentration in Neuroscience from the University of Illinois Chicago.
This person is not in any teams
This person is not in any offices
Cereno Scientific
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.